Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era-Reference-Cited by-同舟云学术

Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era

Published:2009-10 Issue:10 Volume:100 Page:1842-1847
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:

Author:

Seki Ritsuko,Ohshima Koichi,Fujisaki Tomoaki,Uike Naokuni,Kawano Fumio,Gondo Hisashi,Makino Shigeyoshi,Eto Tetsuya,Moriuchi Yukiyoshi,Taguchi Fumihiro,Kamimura Tomohiko,Tsuda Hiroyuki,Ogawa Ryosuke,Shimoda Kazuya,Yamashita Kiyoshi,Suzuki Keiko,Suzushima Hitoshi,Tsukazaki Kunihiro,Higuchi Masakazu,Utsunomiya Atae,Iwahashi Masahiro,Imamura Yutaka,Tamura Kazuo,Suzumiya Junji,Yoshida Minoru,Abe Yasunobu,Matsumoto Tadashi,Okamura Takashi

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2009.01268.x/fullpdf

Reference34 articles.

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project;Okamura;N Engl J Med,1993

2. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma;Kramer;Blood,1998

3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma;Fisher;N Engl J Med,1993

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

5. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients;Applied Immunohistochemistry & Molecular Morphology;2024-06-14

2. A Multicenter Study of Clinicopathology and Immunohistochemical Distinction between Adult and Pediatric Large B-Cell Lymphoma;Fetal and Pediatric Pathology;2022-09-15

3. Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group;Brain Tumor Pathology;2022-03-21

4. Primary Central Nervous System Lymphoma : An Update;Japanese Journal of Neurosurgery;2022

5. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders;Journal of Clinical and Experimental Hematopathology;2021